Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 15;225(4):603-607.
doi: 10.1093/infdis/jiab575.

COVID-19 Vaccination Rates in a Global HIV Cohort

Evelynne S Fulda  1 , Kathleen V Fitch  1 , Edgar T Overton  2 , Markella V Zanni  1 , Judith A Aberg  3 , Judith S Currier  4 , Michael T Lu  5 , Carlos Malvestutto  6 , Carl J Fichtenbaum  7 , Esteban Martinez  8 , Triin Umbleja  9 , Pamela S Douglas  10 , Heather J Ribaudo  9 , Steven K Grinspoon  1
Affiliations

COVID-19 Vaccination Rates in a Global HIV Cohort

Evelynne S Fulda et al. J Infect Dis. .

Abstract

Little is known regarding coronavirus disease 2019 (COVID-19) vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) compared to region- and country-specific vaccination data. The global probability of COVID-19 vaccination through end of July 2021 was 55% among REPRIEVE participants with rates varying substantially by Global Burden of Disease (GBD) superregion. Among PWH, factors associated with COVID-19 vaccination included residence in high-income regions, age, white race, male sex, body mass index, and higher cardiovascular risk. Clinical Trials Registration. NCT02344290.

Keywords: COVID-19; Global Burden of Disease region; human immunodeficiency virus; vaccination.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Vaccination rates among Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) participants and the general population. A, Kaplan-Meier curve depicting probability of vaccination among REPRIEVE participants through July 2021. B, Kaplan-Meier curve depicting probability of vaccination among REPRIEVE participants by Global Burden of Disease (GBD) superregion. C, Comparisons of vaccination rates between people with HIV in REPRIEVE and the general and eligible populations among GBD superregions.
Figure 2.
Figure 2.
Cumulative probability of vaccination over time among Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) participants by race and sex. A, Vaccination rates among Global Burden of Disease (GBD) superregions by race. B, Vaccination rates among each GBD superregion by sex. Participants with no follow-up in 2021 are censored at 1 January 2021. X-axis tick marks indicate the end of a given month.
See this image and copyright information in PMC

References

    1. Ritchie H, Mathieu E, Rodés-Guirao L, et al. Coronavirus pandemic (COVID-19). https://ourworldindata.org/coronavirus. Accessed September 2, 2021.
    1. Bhaskaran K, Rentsch CT, MacKenna B, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV 2021; 8:e24–32. - PMC - PubMed
    1. Childs K, Post FA, Norcross C, et al. Hospitalized patients with COVID-19 and human immunodeficiency virus: a case series. Clin Infect Dis 2020; 71:2021–2. - PMC - PubMed
    1. Grinspoon SK, Fitch KV, Overton ET, et al. ; REPRIEVE Investigators. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Am Heart J 2019; 212:23–35. - PMC - PubMed
    1. Douglas PS, Umbleja T, Bloomfield GS, et al. Cardiovascular risk and health among people with HIV eligible for primary prevention: insights from the REPRIEVE trial [published online ahead of print 16 June 2021]. Clin Infect Dis doi: 10.1093/cid/ciab552. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

Associated data